Vertex Pharmaceuticalsの空売り状況は、投資家がVertex Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報, 空売り情報

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Analyst Ratings

VRTX

Vertex Pharmaceuticals（NASDAQ:VRTX）に14人のアナリストが過去3か月間で分析を行ったところ、その視点は強気から弱気まで多様なものとなった。

14人のアナリスト分析からVertexの市場動向を追う

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

VERTEX PHARMACEUTICALS ORD

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and lowers the price target from $431 to $425.

News

Price Target

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425

15 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $500.53, a high estimate of $600.00, and a low estimate of $376.00. Witnessing a positive shift, the current average has risen by 8.29% from the previous average price target of $462.20.
<img src="https://www.benzinga.com/files/images/story/2024/1727784076_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Vertex Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$474.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$510.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$508.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$509.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$558.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$535.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$376.00</td>
<td>$371.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$455.00</td>
<td>$402.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Vertex Pharmaceuticals's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>About Vertex Pharmaceuticals</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.11% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -135.83%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -21.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -16.32%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Vertex Pharmaceuticals Stock

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $462 to $474.

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $474

Biotech

General

Vertex Announces Health Canada Acceptance Of New Drug Submission For Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Treatment For Cystic Fibrosis

Health Canada Approves CASGEVY (Exagamglogene Autotemcel), The First CRISPR/Cas9 Gene-Edited Therapy, For Treatment Of Sickle Cell Disease And Transfusion-Dependent Beta Thalassemia In Patients 12 And Older

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an average annual return of 18.94%. Currently, Vertex Pharmaceuticals has a market capitalization of $119.59 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,217.85 today based on a price of $463.36 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727276412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,200 Today

16 analysts have expressed a variety of opinions on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of $600.00, and a low estimate of $376.00. Surpassing the previous average price target of $467.40, the current average has increased by 8.77%.
<img src="https://www.benzinga.com/files/images/story/2024/1726772730_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Vertex Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$600.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$510.00</td>
<td>$505.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$550.00</td>
<td>$508.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$509.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$558.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$535.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Sell</td>
<td>$376.00</td>
<td>$371.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$500.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$455.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Steve Chesney</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$545.00</td>
<td>-</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$555.00</td>
<td>$540.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vertex Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Vertex Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Vertex Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>Discovering Vertex Pharmaceuticals: A Closer Look</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Vertex Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.11% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -135.83%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -21.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.32%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews

RBC Capital analyst Brian Abrahams reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and maintains $431 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has fallen 13.71% since its last report. The company recently reported that it has 4.38 million shares sold short, which is 1.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726689614_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.15%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Vertex Pharmaceuticals's Recent Short Interest

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 13.03% on an annualized basis producing an average annual return of 21.14%. Currently, Vertex Pharmaceuticals has a market capitalization of $120.74 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,331.39 today based on a price of $467.79 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725645628_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years

Financial giants have made a conspicuous bullish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) revealed 9 unusual trades.
Delving into the details, we found 55% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $415,070, and 3 were calls, valued at $343,350.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $480.0 to $500.0 for Vertex Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vertex Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vertex Pharmaceuticals's significant trades, within a strike price range of $480.0 to $500.0, over the past month.
<h3>Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724958965_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$30.6</td>
<td>$29.5</td>
<td>$29.5</td>
<td>$500.00</td>
<td>$200.6K</td>
<td>42</td>
<td style="text-align: right;">115</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$34.0</td>
<td>$33.1</td>
<td>$34.0</td>
<td>$500.00</td>
<td>$170.0K</td>
<td>464</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$14.7</td>
<td>$14.3</td>
<td>$14.3</td>
<td>$500.00</td>
<td>$143.0K</td>
<td>392</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$30.6</td>
<td>$29.6</td>
<td>$29.7</td>
<td>$500.00</td>
<td>$74.2K</td>
<td>42</td>
<td style="text-align: right;">36</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$22.9</td>
<td>$21.5</td>
<td>$22.9</td>
<td>$480.00</td>
<td>$41.2K</td>
<td>1.1K</td>
<td style="text-align: right;">28</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Having examined the options trading patterns of Vertex Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Vertex Pharmaceuticals</h3>
<ul>
<li>With a volume of 403,820, the price of VRTX is up 0.54% at $492.36. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 67 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertex Pharmaceuticals</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $537.8.
<ul>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $480.</li>
<li>Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Vertex Pharmaceuticals, targeting a price of $600. </li>
<li>Reflecting concerns, an analyst from Barclays lowers its rating to Equal-Weight with a new price target of $509.</li>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Vertex Pharmaceuticals with a target price of $550. </li>
<li>An analyst from Truist Securities has revised its rating downward to Buy, adjusting the price target to $550. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Vertex Pharmaceuticals options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Vertex Pharmaceuticals's Options Frenzy: What You Need to Know

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40138336/vertex-pharmaceuticals-lifts-annual-guidance-positive-growth-for-its-cystic-fibrosi">is &#8220;great.&#8221;</a>
On Aug. 1, Vertex Pharmaceuticals reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex raised its 2024 product revenue guidance from $10.55 billion-$10.75 billion to $10.65 billion-$10.85 billion.
When asked about Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>), he said, &#8220;We're not recommending companies that lose a ton of money because it's just not the right time.&#8221;
On Aug. 28, Serve Robotics announced closing of $20 million private placement &amp; warrant exercise.
Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) can &#8220;go higher,&#8221; Cramer said, &#8220;This is precisely the kind of stock you should be buying at this stage in the cycle. Hold on.&#8221;
On Aug. 6, Builders FirstSource reported second-quarter adjusted earnings per share of $3.50, beating the street view of $3.02. Quarterly sales of $4.456 billion missed the street view of $4.483 billion.
&#8220;Here's the problem: it costs so much money to build the factories, they're going to have to get a takeover to be able to do that,&#8221; Cramer said about Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>).
On July 24, Viking Therapeutics reported better-than-expected second-quarter EPS results.
Price Action:
<ul>
<li>Serve Robotics shares fell 1.3% to settle at $9.35 on Wednesday.</li>
<li>Builders FirstSource shares fell 1% to close at $172.90.</li>
<li>Vertex Pharmaceuticals shares gained 2% to close at $489.73.</li>
<li>Viking Therapeutics shares fell 0.4% to settle at $61.16 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40600017/wall-streets-most-accurate-analysts-spotlight-on-3-materials-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Materials Stocks Delivering High-Dividend Yields</a></li>
</ul>

BLDR

SERV

VKTX

Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has risen 23.12% since its last report. The company recently reported that it has 5.08 million shares sold short, which is 1.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.66 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724777111_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

High-rolling investors have positioned themselves bearish on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VRTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 12 options trades for Vertex Pharmaceuticals. This is not a typical pattern.
The sentiment among these major traders is split, with 8% bullish and 83% bearish. Among all the options we identified, there was one put, amounting to $55,692, and 11 calls, totaling $435,054.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $485.0 to $510.0 for Vertex Pharmaceuticals over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $485.0 to $510.0 in the last 30 days. 
<h3>Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724436306_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/30/24</td>
<td>$4.4</td>
<td>$4.3</td>
<td>$4.4</td>
<td>$485.00</td>
<td>$55.6K</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">150</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$24.8</td>
<td>$24.0</td>
<td>$24.0</td>
<td>$510.00</td>
<td>$48.0K</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">138</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$24.4</td>
<td>$23.7</td>
<td>$23.8</td>
<td>$510.00</td>
<td>$47.4K</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.1</td>
<td>$24.3</td>
<td>$24.5</td>
<td>$510.00</td>
<td>$44.1K</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$24.8</td>
<td>$24.1</td>
<td>$24.1</td>
<td>$510.00</td>
<td>$43.3K</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">156</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Vertex Pharmaceuticals</h3>
<ul>
<li>With a volume of 284,458, the price of VRTX is up 0.65% at $482.99. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 73 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 13.22% on an annualized basis producing an average annual return of 21.66%. Currently, Vertex Pharmaceuticals has a market capitalization of $125.87 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,896.18 today based on a price of $487.66 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724257817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,900 Today

Editor&#8217;s Note: The headline has been revised for clarity.
Renaissance Technologies, the hedge fund founded by legendary mathematician and former National Security Agency code breaker Jim Simons, recently disclosed its <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves">latest stock holdings in a 13F filing</a> with the U.S. Securities and Exchange Commission on Aug. 9. 
What Happened:&nbsp;The filing <a href="https://www.sec.gov/Archives/edgar/data/1037389/000103738924000073/xslForm13F_X02/renaissance13Fq22024_holding.xml">reveals</a> significant changes in the fund&#8217;s portfolio, reflecting the quantitative strategies that have made Renaissance one of the most successful hedge funds in history.
Leading the pack is Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), a Danish pharmaceutical giant, which accounts for 2.22% of Renaissance&#8217;s portfolio with a market value of $1.3 billion. Despite a 15.03% reduction in shares, NVO remains the fund&#8217;s top holding.
In a notable shift, Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) ranks second, comprising 1.70% of the portfolio. However, Renaissance decreased its PLTR position by 16.56%, signaling a potential reassessment of the data analytics firm&#8217;s prospects.
NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), a leader in AI and graphics processing, saw a significant increase in Renaissance&#8217;s holdings. The fund boosted its NVDA shares by 27.52%, making it the third-largest position at 1.47% of the portfolio.
Other top holdings include Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>), underscoring Renaissance&#8217;s interest in the healthcare sector.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) saw a significant reduction of 33.39% in shares held, now representing 0.89% of the portfolio. Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) also experienced a substantial decrease of 23.11%, accounting for 0.87% of Renaissance&#8217;s holdings with a market value of $515.76 million.
Notably, Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) appears as a new position in the portfolio, claiming the ninth spot with 0.80% of total holdings and a market value of $472.21 million.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) completes the top 10, with Renaissance increasing its stake by 14.20%. TSLA now represents 0.69% of the portfolio, valued at $405.94 million.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/08/40436129/more-than-half-of-fortune-500-companies-flag-ai-as-a-major-risk-marking-473-5-surge-in-warnings-amid">More Than Half Of Fortune 500 Companies Flag AI As A Major Risk, Marking 473.5% Surge In Warnings Amid Growing Concerns</a>
Why It Matters: This latest 13F offers a glimpse into the investment strategies of Renaissance Technologies, now led by CEO Peter Brown following the <a href="https://www.benzinga.com/news/large-cap/23/09/34771681/hedge-fund-titan-peter-brown-built-a-large-language-model-35-years-ago-read-what-it-wrote">recent passing of Simons</a>. The fund continues to leverage complex mathematical models and algorithmic trading, an approach pioneered by Simons that has consistently outperformed traditional investment methods.
Renaissance&#8217;s Medallion Fund, renowned for its exceptional performance, has delivered annual returns of 62% (37% after fees) between 1988 and 2021. This track record has solidified Simons&#8217; legacy as <a href="https://www.benzinga.com/news/24/04/38431687/jim-simons-a-math-professor-became-one-of-the-most-successful-investors-of-all-time-now-he-shares-hi">one of the greatest investors of all time</a>, surpassing even Warren Buffett in terms of returns.
At the time of his death, Simons&#8217; <a href="https://www.benzinga.com/news/24/05/38768433/jim-simons-groundbreaking-quantitative-hedge-fund-founder-who-provided-exceptional-returns-for-inves">net worth was estimated</a> at $31.4 billion, according to Forbes. His legacy extends beyond finance, with significant philanthropic contributions to mathematics and science education. Notably, in 1964, Simons took a highly classified position at the Institute for Defense Analyses, supporting the NSA in cracking Soviet codes and ciphers.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40435655/warren-buffetts-189b-cash-pile-not-a-sign-of-looming-market-crash-says-fund-manager-everybody-gets-e">Warren Buffett&#8217;s $189B Cash Pile Not A Sign Of Looming Market Crash, Says Fund Manager: &#8216;Everybody Gets Excited&#8230; But It&#8217;s Not That Big Of A Number&#8217;</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editor

Equities

ABNB

AVGO

NVDA

PLTR

TSLA

UTHR

NSA Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VTRS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$13.00</td>
<td>$68.0K</td>
<td>2.2K</td>
<td>4.8K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$530.00</td>
<td>$167.9K</td>
<td>4.3K</td>
<td>2.1K</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$57.50</td>
<td>$25.1K</td>
<td>2.5K</td>
<td>843</td>
</tr>
<tr>
<td>ZBH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$110.00</td>
<td>$56.2K</td>
<td>172</td>
<td>786</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/20/24</td>
<td>$320.00</td>
<td>$142.5K</td>
<td>879</td>
<td>505</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$185.00</td>
<td>$140.0K</td>
<td>750</td>
<td>218</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$80.2K</td>
<td>0</td>
<td>200</td>
</tr>
<tr>
<td>ZVRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$6.00</td>
<td>$46.5K</td>
<td>3</td>
<td>90</td>
</tr>
<tr>
<td>GSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$47.00</td>
<td>$38.4K</td>
<td>3</td>
<td>62</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$75.00</td>
<td>$38.1K</td>
<td>151</td>
<td>58</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VTRS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), we notice a call option sweep that happens to be bullish, expiring in 155 day(s) on January 17, 2025. This event was a transfer of 1361 contract(s) at a $13.00 strike. This particular call needed to be split into 62 different trades to become filled. The total cost received by the writing party (or parties) was $68.0K, with a price of $50.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4856 contract(s) were bought and sold. 
• Regarding VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we observe a call option trade with bullish sentiment. It expires in 36 day(s) on September 20, 2024. Parties traded 2099 contract(s) at a $530.00 strike. The total cost received by the writing party (or parties) was $167.9K, with a price of $80.0 per contract. There were 4314 open contracts at this strike prior to today, and today 2102 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bearish sentiment. It expires in 64 day(s) on October 18, 2024. Parties traded 100 contract(s) at a $57.50 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $25.1K, with a price of $253.0 per contract. There were 2515 open contracts at this strike prior to today, and today 843 contract(s) were bought and sold. 
• For ZBH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>), we notice a put option sweep that happens to be bearish, expiring in 36 day(s) on September 20, 2024. This event was a transfer of 205 contract(s) at a $110.00 strike. This particular put needed to be split into 27 different trades to become filled. The total cost received by the writing party (or parties) was $56.2K, with a price of $275.0 per contract. There were 172 open contracts at this strike prior to today, and today 786 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with neutral sentiment. It expires in 36 day(s) on September 20, 2024. Parties traded 216 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $142.5K, with a price of $660.0 per contract. There were 879 open contracts at this strike prior to today, and today 505 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a put option sweep with bearish sentiment. It expires in 155 day(s) on January 17, 2025. Parties traded 203 contract(s) at a $185.00 strike. This particular put needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $140.0K, with a price of $690.0 per contract. There were 750 open contracts at this strike prior to today, and today 218 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with neutral sentiment. It expires in 190 day(s) on February 21, 2025. Parties traded 200 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $80.2K, with a price of $401.0 per contract. There were 0 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• For ZVRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>), we notice a call option sweep that happens to be bullish, expiring in 36 day(s) on September 20, 2024. This event was a transfer of 300 contract(s) at a $6.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $46.5K, with a price of $155.0 per contract. There were 3 open contracts at this strike prior to today, and today 90 contract(s) were bought and sold. 
• Regarding GSK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), we observe a put option sweep with bearish sentiment. It expires in 190 day(s) on February 21, 2025. Parties traded 62 contract(s) at a $47.00 strike. This particular put needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $38.4K, with a price of $620.0 per contract. There were 3 open contracts at this strike prior to today, and today 62 contract(s) were bought and sold. 
• Regarding DXCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), we observe a call option trade with bearish sentiment. It expires in 127 day(s) on December 20, 2024. Parties traded 57 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $38.1K, with a price of $670.0 per contract. There were 151 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

AMGN

DOCS

DXCM

VTRS

ZVRA

10 Health Care Stocks With Whale Alerts In Today's Session

Investors with significant funds have taken a bearish position in Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in VRTX usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for Vertex Pharmaceuticals. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 12% being bullish and 75% bearish. Of all the options we discovered, 7 are puts, valued at $298,503, and there was a single call, worth $28,750.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $420.0 to $450.0 for Vertex Pharmaceuticals during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vertex Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vertex Pharmaceuticals's significant trades, within a strike price range of $420.0 to $450.0, over the past month.
<h3>Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723229152_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$22.8</td>
<td>$19.1</td>
<td>$22.64</td>
<td>$450.00</td>
<td>$54.2K</td>
<td style="text-align: right;">102</td>
<td style="text-align: right;">287</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$22.3</td>
<td>$20.5</td>
<td>$22.3</td>
<td>$450.00</td>
<td>$51.3K</td>
<td style="text-align: right;">102</td>
<td style="text-align: right;">96</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$22.3</td>
<td>$22.2</td>
<td>$22.38</td>
<td>$450.00</td>
<td>$49.1K</td>
<td style="text-align: right;">102</td>
<td style="text-align: right;">144</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$22.8</td>
<td>$21.7</td>
<td>$22.1</td>
<td>$450.00</td>
<td>$44.2K</td>
<td style="text-align: right;">102</td>
<td style="text-align: right;">262</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$22.0</td>
<td>$20.9</td>
<td>$21.95</td>
<td>$450.00</td>
<td>$43.8K</td>
<td style="text-align: right;">102</td>
<td style="text-align: right;">238</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Having examined the options trading patterns of Vertex Pharmaceuticals, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Vertex Pharmaceuticals</h3>
<ul>
<li>With a volume of 415,873, the price of VRTX is down -0.03% at $465.84. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 87 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $500.0.
<ul>
<li>An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Vertex Pharmaceuticals, maintaining a target price of $600. </li>
<li>An analyst from Piper Sandler persists with their Overweight rating on Vertex Pharmaceuticals, maintaining a target price of $535. </li>
<li>An analyst from Canaccord Genuity persists with their Sell rating on Vertex Pharmaceuticals, maintaining a target price of $376. </li>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $480.</li>
<li>An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $509. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Editas Medicine, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/edit#NASDAQ">EDIT</a>) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.
Collaboration and other research and development (R&amp;D) revenues, which comprise the company&#39;s top line, were $0.5 million in the second quarter, down from $2.9 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. The year-over-year decline in revenues can be attributed to reduced drug supply activity with collaborators.
Shares of Editas were down 12.2% on Aug 7 following the announcement of the results.
<h3>Quarter in Detail</h3>
In the second quarter of 2024, R&amp;D expenses increased 82% to $54.2 million compared with $29.8 million reported in the year-ago period. The massive uptick in R&amp;D expenses can be attributed to higher&nbsp;clinical and manufacturing costs related to the accelerated progression of Editas&#39; reni-cel program as well as costs attributable to&nbsp;other&nbsp;research activities.
General and administrative expenses were $18.2 million in the reported quarter, up 6% year over year, due to higher intellectual property and patent-related fees due to increased legal activity.
Editas had cash, cash equivalents and investments worth $318.3&nbsp;million as of Jun&nbsp;30, 2024, down from $376.8 million recorded as of Mar 31, 2024. The company expects its existing cash, cash equivalents and marketable securities, together with the near-term annual license fees and the contingent upfront payment from&nbsp;Vertex Pharmaceuticals&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vrtx#NASDAQ">VRTX</a>), to fund operating expenses and capital expenditure in 2026.
In late 2023, Vertex&nbsp;in-licensed&nbsp;rights to Editas&#39; Cas9 gene editing tool to develop its newly approved sickle cell disease gene therapy, Casgevy.
Shares of Editas have plunged 59.4% year to date compared with the&nbsp;industry&#39;s decline of 4.4%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/06/73699.jpg?v=2014758018" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h3>Pipeline Updates</h3>
Editas has no approved products in its portfolio at the moment. Therefore, pipeline development remains the key focus of the company.
The company is evaluating the safety and efficacy of its investigational gene-editing medicine, reni-cel (renizgamglogene autogedtemcel, previously EDIT-301), in phase I/II/III RUBY study for treating SCD.
EDIT has completed enrollment and continues to dose SCD patients in the adult cohort of the RUBY study. The company has completed enrollment in the adolescent cohort of the RUBY study. Editas remains on track to report substantive data from the RUBY study by the end of 2024.
The company is also evaluating reni-cel for the treatment of transfusion-dependent beta thalassemia (TDT). Editas has completed enrollment in the adult cohort and continues to dose patients in the EdiTHAL study for TDT. The company is also on track to report additional clinical data from the EdiTHAL study by the end of 2024.
Please note that during the reported quarter, Editas reported&nbsp;new positive data from the RUBY study of reni-cel in 18 patients with SCD and the EdiTHAL study of the same in seven patients with TDT. In the expected data readout from the RUBY and EdiTHAL studies by year-end, EDIT will provide additional efficacy data.
<div class="chart_embed">
<h3>Editas Medicine, Inc. Price and Consensus</h3>
<img alt="Editas Medicine, Inc. Price and Consensus" src="https://staticx-tuner.zacks.com/images/charts/d5/1723118191.png" style="height:310px; width:600px" title="" />
Editas Medicine, Inc. price-consensus-chart | Editas Medicine, Inc. Quote
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
Editas currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Annovis Bio (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/anvs#NYSE">ANVS</a>) and&nbsp;Akero Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/akro#NASDAQ">AKRO</a>), each carrying a Zacks Rank #2 (Buy) at present.
In the past 60 days, the Zacks Consensus Estimate for Annovis&#39; 2024 loss per share has remained constant at $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $1.95 to $1.91. Year to date, shares of ANVS have plunged 57.1%.
ANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.
In the past 60 days, estimates for Akero Therapeutics&#39; 2024 loss per share have narrowed from $3.87 to $3.82. During the same period, loss per share estimates for 2025 have remained constant at $4.29. Year to date, shares of AKRO have gained 1.4%.
Akero&#39;s earnings beat estimates in one of the trailing four quarters, missed twice and matched once, delivering an average negative surprise of 5.10%.
<a href="https://www.zacks.com/stock/news/2319312/editas-edit-q2-earnings-revenues-miss-estimates-stock-down?cid=CS-BENZ-FT-analyst_blog|earnings_article-2319312">To read this article on Zacks.com click here.</a>

Earnings

Earnings Misses

Penny Stocks

Small Cap

AKRO

ANVS

EDIT

Editas Q2 Earnings & Revenues Miss Estimates, Stock Down

<ul>
<li>- Eligible transfusion-dependent beta thalassemia (TDT) patients in England will be able to access the therapy from today -</li>
<li>- CASGEVY is one of the first medicines funded by NHS England&#39;s Innovative Medicines Fund -</li>
</ul>

Reported Earlier, Vertex Secures NHS England Reimbursement For Groundbreaking CASGEVY Therapy For Transfusion-Dependent Beta Thalassemia

bluebird bio: Scientific Success And Financial Success, And The Gap Between

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...

Evercore ISI Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $4...

Maintaining Hold Rating on Vertex Pharmaceuticals Amidst LSR Trial Uncertainties

Analyst William Pickering of Bernstein maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $502.00....

Vertex Pharmaceuticals Hold Rating: Cautious Optimism and Risk-Reward Analysis Amidst LSR Trial Anticipation

Avidity gets FDA partial clinical hold lifted on DM1 drug candidate

DBS analyst Mark Kong CFA has maintained their neutral stance on VRTX stock, giving a Hold rating yesterday. Mark Kong CFA has given his Hold ratin...

Vertex Pharmaceuticals: Balancing Robust CF Market Presence with Regulatory Risks and Pipeline Uncertainties

Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX – Research Report), Vertex Pharmaceutical...

Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)

CRISPR Therapeutics ($CRSP), based in Switzerland, commands a lofty valuation when assessing near-term metrics, but the profit opportunity is consi...

CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts

Capricor stock rallies 20% on DMD data presentation update

Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up

BEAM

BLUE

CAPR

CPRX

CRSP

EWTX

MSCLF

MXCT

PEPG

RGNX

RHHBY

SLDB

SRPT

TMDX

TRDA

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Press Releases

Genomics plc Announces New Extension and Expansion of Drug Discovery Collaboration with Vertex

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain

Vertex Reports Second Quarter 2024 Financial Results

Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England

Vertex to Participate in Upcoming September Investor Conferences

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference

Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis

Comments

Vertex Pharmaceuticals

空売り

Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル